[Recent trends in the therapy of hepatitis C]
- PMID: 12910808
[Recent trends in the therapy of hepatitis C]
Abstract
The treatment of HCV correlated hepatitis is an important argument, because of the great incidence and prevalence of this disease. At the end of the Eighties, the IFN was the first substance used for HCV correlated hepatitis therapy. The IFN monotherapy with a dose of 3-6 MU for 6-12 months eradicates the infection in the 15% of cases, and cause an histological temporary improvement in a variable number of patients that keep the infection. In the following years, the research on evaluation of the efficacy of the recombinant interferons or interferons made with genetics engineering (IFN alpha 2a, IFN alpha 2b and IFN Consensus) has given results comparable with the results obtained with IFN alpha. Later, it started the experimentations with IFN associated to other substances, for example IFN-ribavirin combination therapy. The treatment IFN-Ribavirin eradicates the infection in 30% of the patients with the genotype 1b and in 60% with the genotype 2 or 3, while this treatment is less efficacious in the patients with the genotype 4. Recently, it started to use the PEG IFN. The pegylation is the combination of a polietylen-glicole molecule with the IFN molecule, so as to prolong its half-life and reduce the dose only one a week, with reduction of the collateral effects. Some studies has shown that the use of PEG-IFN in monotherapy could help the patients with advanced liver complaint. Successive studies are directed to show the efficacy of the PEG-IFN and ribavirin combination therapy. Recent researches put in evidence new substances, that could represent the future for HCV correlated hepatitis therapy. Between these substances we have to highlight the interleukin, the inhibitors of the viral multiplication and the inhibitors of IMPDH (Inosine monophosphate dehydrogenase). At the beginning of 2002 has made the improvement of HCV vaccine known. Actually, in the USA there are in progress human experimentations, and the production of gamma-globuline, that could be effective to prevent the infection.
Similar articles
-
Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.Am J Gastroenterol. 2005 Nov;100(11):2447-52. doi: 10.1111/j.1572-0241.2005.00253.x. Am J Gastroenterol. 2005. PMID: 16279899 Clinical Trial.
-
Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.J Gastroenterol Hepatol. 2006 Jul;21(7):1177-83. doi: 10.1111/j.1440-1746.2006.04311.x. J Gastroenterol Hepatol. 2006. PMID: 16824072
-
Treatment of chronic hepatitis C in southern Taiwan.Intervirology. 2006;49(1-2):99-106. doi: 10.1159/000087271. Intervirology. 2006. PMID: 16166797 Review.
-
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.Gastroenterology. 2007 Apr;132(4):1270-8. doi: 10.1053/j.gastro.2007.01.041. Epub 2007 Jan 25. Gastroenterology. 2007. PMID: 17408662 Clinical Trial.
-
[Treatment of hepatitis C virus infection].Praxis (Bern 1994). 2005 May 4;94(18):721-6. doi: 10.1024/0369-8394.94.18.721. Praxis (Bern 1994). 2005. PMID: 15938383 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials